A method for determination of the inhibition of xanthine oxidase activity in plasma during allopurinol treatment

I. Németh, D. Boda

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

A micromethod suitable for measuring the combined blood levels of allopurinol and alloxanthine has been developed. The two compounds display marked inhibition of xanthine oxidase activity (Ki=6.3×10-10 and 5.4×10-10 M), so the amounts found in 20 μl serum from allopurinol-treated patients can cause marked inhibition of xanthine oxidase activity in vitro under appropriate conditions. If the concentrations of compounds acting in an 'allopurinol-like' manner are expressed in terms of allopurinol, activity equivalent values are obtained which reflect the effective drug concentration during therapy. The procedure is simple and suitable for serial examinations. It also satisfies the demands of the clinician, in that it can reveal any disturbance in the absorption of allopurinol and in excretion of the drug and its active metabolite, alloxanthine.

Original languageEnglish
Pages (from-to)423-428
Number of pages6
JournalEuropean Journal of Clinical Pharmacology
Volume13
Issue number6
DOIs
Publication statusPublished - Nov 1978

Fingerprint

Allopurinol
Xanthine Oxidase
Oxypurinol
Therapeutics
Pharmaceutical Preparations
Serum

Keywords

  • Allopurinol
  • alloxanthine
  • combined blood level
  • enzyme inhibition
  • xanthine oxidase

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

@article{505155af594c4cf0a801591ffaa53876,
title = "A method for determination of the inhibition of xanthine oxidase activity in plasma during allopurinol treatment",
abstract = "A micromethod suitable for measuring the combined blood levels of allopurinol and alloxanthine has been developed. The two compounds display marked inhibition of xanthine oxidase activity (Ki=6.3×10-10 and 5.4×10-10 M), so the amounts found in 20 μl serum from allopurinol-treated patients can cause marked inhibition of xanthine oxidase activity in vitro under appropriate conditions. If the concentrations of compounds acting in an 'allopurinol-like' manner are expressed in terms of allopurinol, activity equivalent values are obtained which reflect the effective drug concentration during therapy. The procedure is simple and suitable for serial examinations. It also satisfies the demands of the clinician, in that it can reveal any disturbance in the absorption of allopurinol and in excretion of the drug and its active metabolite, alloxanthine.",
keywords = "Allopurinol, alloxanthine, combined blood level, enzyme inhibition, xanthine oxidase",
author = "I. N{\'e}meth and D. Boda",
year = "1978",
month = "11",
doi = "10.1007/BF00566320",
language = "English",
volume = "13",
pages = "423--428",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - A method for determination of the inhibition of xanthine oxidase activity in plasma during allopurinol treatment

AU - Németh, I.

AU - Boda, D.

PY - 1978/11

Y1 - 1978/11

N2 - A micromethod suitable for measuring the combined blood levels of allopurinol and alloxanthine has been developed. The two compounds display marked inhibition of xanthine oxidase activity (Ki=6.3×10-10 and 5.4×10-10 M), so the amounts found in 20 μl serum from allopurinol-treated patients can cause marked inhibition of xanthine oxidase activity in vitro under appropriate conditions. If the concentrations of compounds acting in an 'allopurinol-like' manner are expressed in terms of allopurinol, activity equivalent values are obtained which reflect the effective drug concentration during therapy. The procedure is simple and suitable for serial examinations. It also satisfies the demands of the clinician, in that it can reveal any disturbance in the absorption of allopurinol and in excretion of the drug and its active metabolite, alloxanthine.

AB - A micromethod suitable for measuring the combined blood levels of allopurinol and alloxanthine has been developed. The two compounds display marked inhibition of xanthine oxidase activity (Ki=6.3×10-10 and 5.4×10-10 M), so the amounts found in 20 μl serum from allopurinol-treated patients can cause marked inhibition of xanthine oxidase activity in vitro under appropriate conditions. If the concentrations of compounds acting in an 'allopurinol-like' manner are expressed in terms of allopurinol, activity equivalent values are obtained which reflect the effective drug concentration during therapy. The procedure is simple and suitable for serial examinations. It also satisfies the demands of the clinician, in that it can reveal any disturbance in the absorption of allopurinol and in excretion of the drug and its active metabolite, alloxanthine.

KW - Allopurinol

KW - alloxanthine

KW - combined blood level

KW - enzyme inhibition

KW - xanthine oxidase

UR - http://www.scopus.com/inward/record.url?scp=0017847813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017847813&partnerID=8YFLogxK

U2 - 10.1007/BF00566320

DO - 10.1007/BF00566320

M3 - Article

VL - 13

SP - 423

EP - 428

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 6

ER -